

Electronic Acknowledgement Receipt

EFS ID:	9403175
Application Number:	10534348
International Application Number:	
Confirmation Number:	4929
Title of Invention:	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
First Named Inventor/Applicant Name:	Karen Silence
Customer Number:	23628
Filer:	Erik J. Spek/Eileen Flaherty
Filer Authorized By:	Erik J. Spek
Attorney Docket Number:	A0848.70005US00
Receipt Date:	08-FEB-2011
Filing Date:	09-MAY-2005
Time Stamp:	19:26:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	Reiter_et_al_NatBiotechnol_1996_v14_p1239.pdf	1536056 9bf5a078ac2ae9211e60f6eb69384a2177095a	no	7

Warnings:

Information:

2	NPL Documents	Reiter_et_al_JMolBiol_1999_v2 90_p685.pdf	332392 53c245bc8f1146d1c3ef3396f313e1ba5 cfcfa8	no	14
Warnings:					

3	NPL Documents	Rheinheimer_et_al_JImmunol_1996_v157_p2989.pdf	1006138 d82c749341a07fca3d65195e4917c62514 65a19	no	9
Warnings:					

4	NPL Documents	Riechmann_et_al_J_ImmunoL_Meth_1999_v231_p25.pdf	1158522 090b69e1110a6e123d055905a177411 bf5ed	no	15
Warnings:					

5	NPL Documents	Riemer_et_al_Molimmunol_2005_v42_p1121.pdf	638216 d424a61b7555b1b91ed516b79ffcc4 246c5	no	4
Warnings:					

6	NPL Documents	Roovers_et_al_CancImmunol_2007_v56_p303.pdf	554887 d4e5793a10514ff8f5c22bf664c861d1305 71ff	no	15
Warnings:					

7	NPL Documents	Rosenberg_AAPSJournal_2006_v8_pE501.pdf	167563 798e51b0655b97d96a6d68e9a938ea1 3d89	no	7
Warnings:					

8	NPL Documents	Saerens_et_al_JMolBiol_2005_v352_p597.pdf	1147766 45d112e1d6d01113c4e2385793167879 d92691	no	11
Warnings:					

9	NPL Documents	Scheurich_et_al_IntJCancer_1986_v38_p127.pdf	567969 d97cab7608969871b75c2bb267ed2ca 9b499	no	7
Warnings:					

10	NPL Documents	Schlaeppi_et_al_JCancerResClinOncol_1999_v125_p336.pdf	675930 56216478936190800063070c680f2a0534 665ce	no	7
Warnings:					

Information:					
---------------------	--	--	--	--	--

11	NPL Documents	Silacci_et_al_Proteomics_2005_v5_p2340.pdf	1498482 07fb024401db51856a9501e96d294ba789fc	no	11
Warnings:					

12	NPL Documents	Smith_et_al_Bioconjugate_Chem_2001_v12_p750.pdf	743990 114238f9a2dd1e0d815c201548d2e4c75cda466b	no	8
Warnings:					

13	NPL Documents	Stahl_et_al_PatholBiol_1997_v45_p66.pdf	1283074 a/4cf02fa10ea3162dfebe566131932f5b24516	no	11
Warnings:					

14	NPL Documents	Stancovski_et_al_PNAS_1991_v88_p8691.pdf	1178830 e/bed279a674150d496c8603b9c75b50a65f	no	5
Warnings:					

15	NPL Documents	Terskikh_et_al_PNAS_1997_v9_4_p1663.pdf	860371 eed0c101e4f7303bf6f628ccce28b6290fe1b5d0	no	6
Warnings:					

16	NPL Documents	Tijink_et_al_MolCancerTher_2008_v7_p2288.pdf	1018552 05a8f83b023bb1c240a8f6f738d49c11d58a5d7	no	10
Warnings:					

17	NPL Documents	van_den_Beucken_JMolBiol_2001_v310_p591.pdf	605179 7959212014a10e5d46b94639617fc5379a5bf2	no	12
Warnings:					

18	NPL Documents	Van_Der_Linden_et_al_J_Immuno_Methods_2000_v240_p185.pdf	1059670 1f3fb909c2c3bb4fd1c9f8ecf20ee713d94	no	11
Warnings:					

19	NPL Documents	Vickers_DrugsAging_2002_v19_p487.pdf	1518765 0xd198fc7709fb2cdff3c3fedc345f18442fc	no	8
Warnings:					

Information:					
---------------------	--	--	--	--	--

20	NPL Documents	VanderVaartetalVaccine2006v2 4p4130.pdf	705638 Dae45d8d49942a2e4a6c1e22cf6a510f9c7 bbbc	no	8
Warnings:					
Information:					
21	NPL Documents	Waldmann_et_al_JClinInvest_1 972_v51_p2162.pdf	2508524 08a0a5cb040d11751b48ab5ff0d1a0fb cb13	no	13
Warnings:					
Information:					
22	NPL Documents	Wesolowski_et_al_MedMicrobi olImmunol_2009_v198_p157. pdf	906381 0f2f2448c489f46ca1c9c2b79ddfc05f c88f5	no	18
Warnings:					
Information:					
23	NPL Documents	Winkler_et_al_J_ImmunoL_200 0_v165_p4505.pdf	3090929 9b979604ec29c161334876318527926fa fbff	no	10
Warnings:					
Information:					
24	NPL Documents	Witte_et_al_Cancer_Metastat_Re v_1998_v17_p155.pdf	689011 5d8f7a6a97928151e8e30150854ed7ec03 662ba	no	7
Warnings:					
Information:					
25	NPL Documents	Zhu_et_al_InvestNewDrugs_19 99_v17_p195.pdf	1455093 8b89e1337480f54419e46166f881b6d 8c991	no	18
Warnings:					
Information:					
Total Files Size (in bytes): 26970928					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.